Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure

Qiu Bo; Zhu Ling; Wang TangMing; Yan ShiChun; Zhang JianMing; Xie ZhiAn; Liu XingYu

doi:10.3969/j.issn.1001-5256.2016.07.017

Issue 7

Jul. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(7): 1300-1304

PDF( 1536 KB)

Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2016.07.017

Research funding:

Published Date: 2016-07-20

Abstract

Abstract

Objective To investigate the efficacy and safety of low- dose glucocorticoids in the treatment of HBV- related acute- on-chronic liver failure( HBV- ACLF). Methods A total of 118 patients with HBV- ACLF who were treated in Center for Liver Disease Treatment in the Fourth People's Hospital of Panzhihua from January 2012 to October 2015 were enrolled and randomly divided into treatment group and control group,with 59 patients in each group. All the patients were given antiviral therapy with entecavir and conventional liver-protecting and symptomatic treatment,and the patients in the treatment group were given intravenous drip of low- dose hydrocortisone sodium succinate( 25 mg / d) in addition. The clinical manifestations,biochemical parameters for liver function,adverse events,length of hospital stay,and hospital costs were recorded for all patients. The t- test was used for comparison of continuous data between groups,the paired t- test was used for comparison of continuous data within groups,and the chi- square test or Fisher's exact test was used for comparison of categorical data between groups. Results At the end of the course of the treatment,the treatment group showed significantly better improvements in the biochemical parameters for liver function( alanine aminotransferase,aspartate aminotransferase,total bilirubin,albumin,cholinesterase,and prothrombin activity) compared with the control group( all P < 0. 001). The treatment group had a significantly shorter length of hospital stay and significantly lower hospital costs than the control group( length of hospital stay: 48. 0 ± 9. 2 d vs 74. 0 ± 16. 4 d,t = 4. 34,P < 0. 01; hospital costs: 7974. 5 ± 853. 7 RMB / person vs 12 432. 7 ± 1263. 1 RMB / person,t = 22. 46,P < 0. 01). No patients in the treatment group experienced adverse events related to hydrocortisone sodium succinate. Conclusion In the treatment of HBV- ACLF,low- dose hydrocortisone sodium succinate can eliminate jaundice,alleviate conditions,and improve the prognosis. Meanwhile,it can also shorten the length of hospital stay and reduce hospital costs. This drug has good safety and holds promise for further clinical research.
- hepatitis B virus,
- liver failure,
- glucocorticoids,
- therapy

FullText(HTML)

References(20)

References

[1]ZHANG YL,HAN T,ZHANG M,et al.Research progress in prognostic markers of acute-on-chronic liver failure[J].J Clin Hepatol,2014,30(10):1078-1081.(in Chinese)张玉玲,韩涛,张敏,等.慢加急性肝衰竭预后标志物的研究进展[J].临床肝胆病杂志,2014,30(10):1078-1081.

[2] Liver Failure and Artificial Liver Group,Chinese Society of Infectious Diseases,CMA;Severe Liver Diseases and Artificial Liver Group,Chinese Society of Hepatology,CMA.Guideline for diagnosis and treatment of liver failure(2012 version)[J].Chin J Clin Infect Dis,2012,5(6):321-327.(in Chinese)中华医学会感染病学分会肝衰竭与人工肝治疗组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2012年版)[J].中华临床感染病杂志,2012,5(6):321-327.

[3]LIU H,CHEN G,GAN XM.Research advances in new approaches to treatment of acute-on-chronic liver failure[J].J Clin Hepatol,2015,31(9):1496-1500.(in Chinese)刘洪,陈刚,甘雪梅.慢加急性肝衰竭治疗的新技术及其研究进展[J].临床肝胆病杂志,2015,31(9):1496-1500.

[4]ZHANG XQ,NIE QH.Application and effect of glucocorticoids in treatment of severe hepatitis[J].J Pract Hepatol,2004,7(2):70-72.(in Chinese)张绪清,聂青和.糖皮质激素在治疗重型肝炎中的应用及评价[J].实用肝脏病杂志,2004,7(2):70-72.

[5]LI LJ,REN H.Infectious Diseases[M].8th ed.Beijing:People's Medical Publishing House,2013:29-30.(in Chinese)李兰娟,任红.传染病学[M].8版.北京:人民卫生出版社,2013:29-30.

[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[7]WANG TM,QIU B,LI SM,et al.Clinical efficacy of lamivudine and thymosinα1 combined with artificial extracorporeal liver support therapy in treatment of severe hepatitis B[J].Chin Hepatol,2008,13(2):145-147.(in Chinese)王堂明,邱波,李树民,等.拉米夫定、胸腺肽α1联合人工肝治疗重型乙型肝炎的临床研究[J].肝脏,2008,13(2):145-147.

[8]XIA SL,HE XF.Efficacy of entecavir treatment for patients with chronic hepatitis B[J].J Clin Hepatol,2015,31(4):523-525.(in Chinese)夏淑林,何小峰.恩替卡韦治疗慢性乙型肝炎的疗效观察[J].临床肝胆病杂志,2015,31(4):523-525.

[9]DENG ZP.Efficacy and safety of entecavir on hepatitis B[J].Chin J New Drugs Clin Remed,2005,24(4):326-329.(in Chinese)邓中平.恩替卡韦治疗乙型肝炎的疗效及安全性[J].中国新药与临床杂志,2005,24(4):326-329.

[10] COURSIN DB,WOOD KE.Corticosteroid supplementation for adrenal insufficiency[J].JAMA,2002,287(2):236-240.

[11]JIANG XH,GU XB.Change in serum cortisol concentration in patients with severe chronic hepatitis and its clinical significance[J].Jiangsu Med J,2004,30(6):464.(in Chinese)蒋祥虎,顾锡炳.慢性重型肝炎血清皮质醇浓度的变化及临床意义[J].江苏医药杂志,2004,30(6):464.

[12]ZHANG L,HAN F,WU D,et al.Relationship between sera hydrocortisone level and the prognosis of fulminant hepatitis[J].JClin Hepatol,2011,27(5):538-539.(in Chinese)张琳,韩峰,吴丹,等.血清皮质醇水平与重型肝炎预后的相关性[J].临床肝胆病杂志,2011,27(5):538-539.

[13]WANG HH.Low-dose corticosteroid therapy for tendency to subacute severe hepatitis:an analysis of 46 cases[J].Pract Clin Med,2001,2(4):22,24.(in Chinese)王汉华.小剂量激素治疗亚急性重症肝炎倾向46例[J].实用临床医学,2001,2(4):22,24.

[14]SUN S.Low-dose corticosteroid therapy for acute hepatitis E-associated hyperbilirubinemia:an analysis of 17 cases[J].Chin J Integr Tradit West Med Liver Dis,2002,12(5):299.(in Chinese)孙苏.小剂量激素治疗急性戊型肝炎高胆红素血症17例[J].中西医结合肝病杂志,2002,12(5):299.

[15]LEI NF,LIU TH,HE ZY.Analysis of blocking effect and safety of glucocorticoid de-escalation combined with antiviral therapy in the treatment of early severe hepatitis B[J].China Prac Med,2015,10(30):5-7.(in Chinese)雷南凤,刘添皇,何宗运.糖皮质激素降阶梯联合抗病毒治疗对早期乙型重症肝炎的阻断效果及安全性分析[J].中国实用医药,2015,10(30):5-7.

[16]CHEN CX,LIU B,GUO SM,et al.Glycocorticosteroid administration prevents occurrence of necrotic hepatitis in patients with chronic hepatitis B of severe degree[J].J Trop Dis Parasitol,2004,2(2):68-74,105.(in Chinese)陈从新,刘波,郭顺明,等.应用糖皮质激素治疗慢性乙型肝炎重度患者阻断坏死性肝炎的发生[J].热带病与寄生虫学,2004,2(2):68-74,105.

[17]ZHOU XS,WAN MB,XUE JY,et al.Effects of glucocorticoids combined with antiviral therapy in treatment of patients with chronic severe hepatitis B[J].J Clin Hepatol,2008,24(2):101-103.(in Chinese)周先珊,万谟彬,薛建亚,等.抗病毒基础上应用糖皮质激素治疗慢性重型乙型肝炎临床分析[J].临床肝胆病杂志,2008,24(2):101-103.

[18]WU JY,LI M,ZHANG H.Effect of glucocorticoid treatment on the clinical ontcome of patients with early-stage liver failure[J].JSouth Med Univ,2011,31(3):554-556.(in Chinese)吴锦瑜,黎明,张华.糖皮质激素治疗对早期肝衰竭患者转归的影响[J].南方医科大学学报,2011,31(3):554-556.

[19]YANG XK,XU GS.Efficacy of glucocorticoid in treatment of HBV-related hepatic failure:a meta-analysis[J].Med J Chin PLA,2013,38(7):581-584.(in Chinese)杨晓鲲,徐贵森.糖皮质激素治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].解放军医学杂志,2013,38(7):581-584.

[20]SONG P,LIU W,LIU TJ,et al.Efficacy and safety of glucocorticoids in treatment of severe chronic hepatitis B:a meta-analysis[J].Chongqing Med,2015,44(24):3407-3410.(in Chinese)宋攀,刘伟,刘天杰,等.糖皮质激素对慢性重度乙型肝炎疗效及安全性的Meta分析[J].重庆医学,2015,44(24):3407-3410.

Relative Articles

[1]	Wenhui WANG, Xuhua DUAN, Hao LI, Shuguang JU, Manzhou WANG, Jianzhuang REN, Xinwei HAN. A cost-effect analysis of transarterial chemoembolization with CalliSpheres beads loaded with arsenic trioxide versus arsenic trioxide iodized oil emulsion in treatment of unresectable liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(9): 2125-2129. doi: 10.3969/j.issn.1001-5256.2021.09.024
[2]	Du YiChao, Zhang Hao, Zhong FuRui, Cheng HuanLi, Lai Li, Qian BaoLin, Tan Peng, Xia XianMing, Fu WenGuang. Protective effect of pinocembrin in a mouse model of liver injury induced by acetaminophen[J]. Journal of Clinical Hepatology, 2020, 36(3): 608-611. doi: 10.3969/j.issn.1001-5256.2020.03.027
[3]	Ha FuShuang, Han Tao, Liang Ning, Nie XinHua, Zhu ZhengYan. Effect of recombinant human granulocyte colony-stimulating factor on rats with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1565-1569. doi: 10.3969/j.issn.1001-5256.2019.07.028
[4]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[5]	Zhang YongChao, Bi YanZhen, Fang Xiao, Wang QuanYi, Wang QuanQuan, Tang HuiXin, Kong LingBin, Chen Yu, Duan ZhongPing, Shu ZhenFeng, Hong Feng. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. Journal of Clinical Hepatology, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
[6]	Wang Hao, He Cheng, Chen Hao, Ou YangZhongMin, Liu ZhiQiang. Value of Gd-EOB-DTPA-enhanced MRI in the assessment of liver function in dogs with acute liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1576-1581. doi: 10.3969/j.issn.1001-5256.2019.07.030
[7]	Zhou QiFeng, Zhang LingQiang, Liao MengJiao, Pang MingQuan, Li MengXuan, Ren Li, Fan HaiNing. Establishment of a subcutaneous xenograft tumor model of alveolar echinococcosis in nude mice[J]. Journal of Clinical Hepatology, 2018, 34(3): 588-590. doi: 10.3969/j.issn.1001-5256.2018.03.028
[8]	Ji JunSong, Chen Ting, Wang Hui, Wang ChenYi, Zhu XinYing, Yin Hao, Fu ZhiRen. Effect of arsenic trioxide chemotherapy on survival time in liver cancer patients undergoing liver transplantation[J]. Journal of Clinical Hepatology, 2017, 33(9): 1745-1748. doi: 10.3969/j.issn.1001-5256.2017.09.023
[9]	Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025
[10]	Chen Jing, Liu XiaoYan, Yang HaoZhen, Huang Kun, Hu JinHua, Xin ShaoJie. Study on p-p38 expression and its significance in liver tissues of mice with acute liver failure and patients with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2015, 31(4): 556-559. doi: 10.3969/j.issn.1001-5256.2015.04.019
[11]	Pang GuoJin, Chen ShuangJun, Zhao WeiHua, Liu TianHui, Wang Ping, You Hong, Cong Min. Dynamic change of hepcidin in liver fibrosis induced by CCl4 among mice[J]. Journal of Clinical Hepatology, 2015, 31(3): 418-423. doi: 10.3969/j.issn.1001-5256.2015.03.025
[12]	Gao ChengGuang, Chen RiXia. Clinical research on treatment of advanced primary liver cancer with combination of thymosin α1 and arsenic trioxide[J]. Journal of Clinical Hepatology, 2015, 31(4): 564-568. doi: 10.3969/j.issn.1001-5256.2015.04.021
[13]	Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
[14]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[15]	Jiang Han, Wang XueFeng, Wang ZiHao, Xu Bin, Shi WeiBin. The establishment of rabbit VX2 hepatic tumor model and the application of nano-scale microbubble contrast agent in the diagnosis of this model[J]. Journal of Clinical Hepatology, 2011, 27(7): 746-748.
[16]	Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272.
[17]	Ye LiHong, Wang ChongKui, Tian YueYang, Xu Yi, Zheng HaoJie, Shao ShiXiang, Dai ErHei. Effect of Ruangan Huajian granule on hepatic expression of PDGF - B in C57 mice with experimental hepatic fibrosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1047-1050.
[18]	Song Yu, Yu Zheng, Fan YanHua, Yao ShuKun, Wang TaiLing. A rat model of hepatic veno-occlusive disease induced by the Gynura root water decoction[J]. Journal of Clinical Hepatology, 2011, 27(8): 860-864.
[19]	Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75.

Supplements(0)

Cited By

Cited by

Periodical cited type(10)

1.	杨晓曼. γ-谷氨酰转移酶/血小板在乙肝肝硬化失代偿期患者中的表达及临床意义. 河南医学研究. 2024(08): 1407-1410 .
2.	刘爱华，符建，陈小红. 瞬时超声弹性成像联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化价值研究. 实用肝脏病杂志. 2023(05): 634-637 .
3.	肖少伟，杜亚哲. γ-谷氨酰转移酶/胆碱酯酶比值与γ-谷氨酰转移酶/血小板比值对慢性乙型肝炎患者肝纤维化程度的预测效能. 实用医技杂志. 2023(11): 812-815 .
4.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
5.	桑阿利. APRI、Fib-4和Fibroscan联合诊断慢性乙型肝炎肝纤维化程度的价值. 甘肃医药. 2022(10): 896-898 .
6.	王晔恺，于倩，姚燕珍，罗雯斌，洪开听，鲍舟君. 对数几率回归模型构建联合预测因子对慢性乙型肝炎患者早期肝硬化诊断的临床应用. 中国卫生检验杂志. 2021(01): 90-93+97 .
7.	陈兴，梁小桃. 肝瞬时弹性成像与天冬氨酸转氨酶/血小板指数在慢性乙型肝炎合并脂肪肝患者肝纤维化诊断中的应用价值. 中国当代医药. 2021(11): 60-62 .
8.	黄腊平，陈焰. 基于Fibroscan技术的柴胡疏肝散对非酒精性脂肪肝患者临床疗效分析. 清远职业技术学院学报. 2020(02): 35-38 .
9.	栗红江，何久胜，胡素玲，何福亮，田彦卿，刘震霞. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能. 临床军医杂志. 2020(09): 1090-1091+1094 .
10.	熊静，林登娜，翁伟镇，陈俊峰，曹会娟，张绍全，张静，高隽，林炳亮. FIB-4联合血清PCⅢ、ⅣC评估乙型肝炎病毒相关肝纤维化. 国际病毒学杂志. 2020(05): 403-406 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2296) PDF downloads(492)

Efficacy of low-dose glucocorticoids in treatment of HBV-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2016.07.017